Author Archives: Forest Ray PhD

Interactive Research, Rehab Center for DBS Opening at Mount Sinai

People with Parkinson’s disease who undergo deep brain stimulation (DBS) at Mount Sinai in New York, along with those scheduled for the surgical treatment, will soon have access to Q-Lab, a newly opening immersive and interactive rehabilitation and research facility. A collaboration between the Nash Family Center…

AbbVie Chooses Two Parkinson’s Therapies to Develop With Mission

AbbVie has selected two drug candidates — both targeting enzymes known as DUBs — for further development as possible Parkinson’s disease treatments, as part of the company’s ongoing collaboration with Mission Therapeutics. “We are delighted to have reached this next major milestone in our collaboration with AbbVie and…

CNM-Au8 Raises Cellular Energy in Brains of Patients in REPAIR-PD Trial

Clene Nanomedicine‘s investigational oral Parkinson’s treatment, CNM-Au8, safely and significantly increased energy metabolism in the brains of patients taking part in the Phase 2 REPAIR clinical trials, top-line results show. Greater energy metabolism is expected to lower oxidative stress in the brain, making more energy available to protect and…

New Algorithm Groups Parkinson’s Symptoms to Predict Progression

Researchers with IBM and the Michael J. Fox Foundation developed a computational model that may help physicians better understand how Parkinson’s disease will progress among individuals. In their study, the algorithm — based on a branch of computer science called machine learning — identified groups of Parkinson’s symptoms and…

Six miRNAs in Blood Show Potential as Biomarkers

Six microRNAs may serve as biomarkers of Parkinson’s disease progression and early diagnosis, a recent study suggests. That study, “Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease,” was published in the journal Translational Neurodegeneration. MicroRNAs (miRNAs)…

Adhera to Develop MLR-1019 for Easing Parkinson’s Symptoms

Adhera Therapeutics will develop MLR-1019 (armesocarb), a treatment candidate for easing Parkinson’s disease symptoms, following a licensing agreement with Melior Pharmaceuticals II. The therapy is the only one in development that’s designed to treat both Parkinson’s motor and non-motor symptoms simultaneously. “MLR-1019 represents what could be…

AC Immune Acquires Experimental Vaccine PD01, Other Therapies

Parkinson’s vaccine candidate Affitope PD01, along with maker Affiris’ portfolio of other alpha-synuclein-targeting therapies, was acquired by AC Immune in a recent deal valued at nearly $60 million. “We believe very strongly that active vaccination will play an important role in the long-term management and possible prevention of…

Hydrogel Device Hints at Better Option for Brain Stimulation

A flexible hydrogel-based device, implanted in the brains of mice, allowed scientists to stimulate and detect brain signals — in deep brain regions — in real time, a study reported. The hydrogel device functions for nearly six months, and triggers less of a reaction and lesser scarring than current electrodes,…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums